A Vessel for Knowledge: The Latest Research & Management Updates for Vasculitis

References

1. Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021 Feb 18;384(7):599–609.
2. Xiao H, Dairaghi DJ, Powers JP, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014 Feb;25(2):225–231.
3. Corbera-Bellalta M, Alba-Rovira R, Muralidharan S, et al. Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Ann Rheum Dis. 2022 Apr;81(4):524–536.
4. Christ L, Seitz L, Scholz G, et al. A proof-of-concept study to assess the efficacy of tocilizumab monotherapy after ultra-short glucocorticoid administration to treat giant cell arteritis-the GUSTO trial [OP0061]. Ann Rheum Dis. 2021;80:33.
5. Kant S, Azar A, Geetha D. Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2022 Feb;101(2):414–415.